There are currently 434 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
NCT04265872
Recruiting
The hypothesis of this pilot trial is that administration of bortezomib will inhibit NHEJ in metastatic TNBC leading at the time of disease progression to metastases that are HR-deficient and sensitive to pembrolizumab and cisplatin therapy. The trial will include in depth analysis of the patients' TNBC genome and phosphoproteome to evaluate HR-proficiency and deficiency, and nuclear proteins that drive NHEJ, before and upon progression with bortezomib therapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas, Texas
Conditions: Breast Cancer
Register for Updates
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
NCT05226871
Recruiting
The purpose of this clinical trial is to provide study medicine(s) and learn about their safety. This study is seeking participants who: * Have benefited from ongoing study treatment as determined by the study doctor in a Pfizer-sponsored palbociclib Parent Study * Must agree to follow the reproductive criteria * Are willing and able to comply with all scheduled visits, treatment plans, and other study procedures * Can give signed informed consent documents Participants in this study will cont... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/02/2025
Locations: UCSF Medical Center at Mission Bay, San Francisco, California +21 locations
Conditions: Breast Cancer, Head and Neck Cancer
Register for Updates
Study of Tucatinib and Doxil in Participants with Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
NCT05748834
Recruiting
This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to: * Learn how well the combination of tucatinib and Doxil works * Learn more about the side effects of the combination of tucatinib and Doxil
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Maryland Oncology Hematology, Columbia, Maryland +7 locations
Conditions: Breast Cancer
Register for Updates
The Care Tracker Study: Using Patient-Reported Data to Address Racial Disparity in Cancer Treatment
NCT06096623
Recruiting
This study assesses the feasibility and acceptability of a brief electronic patient-reported outcome (ePRO) tool that allows patients to self-identify impending delays. The risk of treatment delays according to tumor type and race will be measured by both ePRO and electronic health record (EHR) tools. Data from this study and the association of social determinants of health could be useful to flag patients at risk of delay and due timely intervention for modifiable treatment barriers. The predic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: University of North Carolina, Chapel Hill, North Carolina
Conditions: Cancer, Breast Cancer, Colorectal Cancer
Register for Updates
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer
NCT05216432
Recruiting
This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and/or tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors. It will als... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: The University of Arizona Cancer Center, Tucson, Arizona +35 locations
Conditions: PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Endometrial Cancer
Register for Updates
Taking AIM at Breast Cancer
NCT04720209
Recruiting
The purpose of this research is to determine whether a 16-week exercise program for individuals with breast cancer and have completed treatment (i.e., surgery, chemotherapy, or radiation) for breast cancer will decrease inflammation in fat tissue.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Register for Updates
De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You
NCT05134779
Recruiting
This is a live biobank study for breast cancer (BC) patients where samples will be collected at inflection points in the course of the disease.
Gender:
FEMALE
Ages:
Between 18 years and 90 years
Trial Updated:
01/24/2025
Locations: Brooklyn Methodist Hospital - NewYork Presbyterian, New York, New York +1 locations
Conditions: Breast Cancer
Register for Updates
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
NCT03769415
Recruiting
The HARMONY trial is an interventional trial enrolling metastatic breast cancer (MBC). Current treatment of breast cancer uses clinical subtype information (e.g. hormone receptor-positive (HR+)) to help guide treatment options. Breast cancer can also be characterized by molecular subtype, but it is not known if this information is helpful in determining treatment when breast cancer has become metastatic. HARMONY will give the treating physician of each participant the molecular subtype of the tu... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
01/24/2025
Locations: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina +1 locations
Conditions: Breast Cancer
Register for Updates
Combined Immunotherapies in Metastatic ER+ Breast Cancer
NCT04563507
Recruiting
Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic breast cancer are eligible to a randomized trial. Patients receiving standard first line therapy for metastatic HR+ Breast cancer(BC) (letrozole+palbociclib) are randomly assigned to also receive Stereotactic Body Radiation Therapy(SBRT) to each metastatic lesion.
Gender:
FEMALE
Ages:
Between 18 years and 90 years
Trial Updated:
01/24/2025
Locations: Weill Cornell Medicine, New York, New York +2 locations
Conditions: Breast Cancer
Register for Updates
Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy
NCT04724499
Recruiting
The purpose of this research is to determine whether a 16-week high intensity interval training (HIIT) exercise program will improve brain health among women undergoing chemotherapy and also improve cardiovascular (heart) function. The names of the study interventions involved in this study are/is: * High-Intensity Interval Training (HIIT)
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Breast Cancer, Chemotherapy Effect, Exercise Therapy, Cognitive Change
Register for Updates
A Novel Approach Utilizing Organ Specific Age Proteomics
NCT06789653
Recruiting
This study compares changes in P16INK4A expression and plasma proteomic signatures of specific organ age pre- and post-chemotherapy in women treated with adjuvant chemotherapy for early-stage breast cancer. It aims to determine if biological and accelerated immune aging, assessed using T cells from peripheral blood, represents aging in different organs. Patients receiving chemotherapy, especially adjuvant regimens that include anthracyclines and taxanes, often experience late development of car... Read More
Gender:
FEMALE
Ages:
Between 22 years and 66 years
Trial Updated:
01/23/2025
Locations: University of North Carolina, Chapel Hill, North Carolina
Conditions: Breast Cancer
Register for Updates
Positron Emission Tomography (PET) Imaging with Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
NCT03321045
Recruiting
Our goal is to investigate the use of 89Zr-trastuzumab as a HER2 imaging agent to determine which patients are likely to respond to targeted HER2 agents as single agent therapy. We are proposing to perform a pilot study with goals of demonstrating the feasibility of imaging breast cancer patients with 89Zr-trastuzumab-PET/MRI, evaluating the relationship between tumor 89Zr-trastuzumab uptake and in vitro positivity of HER2, assessing the relationship between 89Zr-trastuzumab uptake and response... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: The Kirklin Clinic, Birmingham, Alabama
Conditions: Breast Cancer
Register for Updates